Effects of Cranberry on Inflammation and Oxidative Stress in CKD
Chronic diseases, including chronic kidney disease (CKD), are among the leading causes of global mortality and morbidity. According to the Global Burden of Disease, in 2017 the global prevalence of CKD was 9.1%, with over 697 million cases and 1.2 million deaths attributed to this condition. Future projections indicate that CKD could become the fifth most common cause of death.
CKD is closely linked to cardiovascular risk, manifesting as coronary artery disease, heart failure, and arrhythmias. In addition to traditional risk factors (diabetes, hypertension, obesity, smoking, and aging), non-traditional factors such as mitochondrial and endothelial dysfunction, oxidative stress, and inflammation also play a role.
One of the main factors involved in chronic kidney disease progression is the production of reactive oxygen species (ROS), which cause oxidative stress and damage to proteins, DNA, and lipids, while also triggering inflammation and vascular and myocardial remodeling.
The Role of Cranberry in CKD
Cranberry (Vaccinium macrocarpon) is known for its rich content of bioactive compounds, such as flavonoids, anthocyanins, and A-type proanthocyanidins (PACs). These polyphenols exhibit antioxidant, anti-inflammatory, and anti-adhesion properties, which could positively impact CKD management.
Preclinical studies have demonstrated that cranberry polyphenols can:
- Reduce ROS production.
- Stimulate Nrf2 activation, a transcription factor regulating antioxidant genes.
- Inhibit NF-kB, a mediator of inflammation.
- Modulate gut microbiota, improving metabolism and reducing oxidative stress.
Cranberry as a Complementary Therapy
Cranberry extracts, often used as dietary supplements, have been studied in conditions such as diabetes, endothelial dysfunction, and metabolic syndrome. However, their potential effects on CKD, particularly inflammation and oxidative stress markers, remain underexplored.
Clinical Study on Cranberry’s Effects on CKD
Study Design
A randomized, double-blind, placebo-controlled clinical trial evaluated the effect of a cranberry extract supplement on patients with stage 3-4 CKD not on dialysis. Participants received 1000 mg/day of cranberry extract or a placebo for two months. Adherence to the treatment was monitored through capsule counts.
Objectives and Measured Parameters
The primary goal was to analyze the expression of transcription factors NF-kB and Nrf2 involved in inflammatory and antioxidant processes. Secondary parameters included:
- Plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6), and lipid peroxidation markers (TBARS).
- Renal function via estimated glomerular filtration rate (eGFR).
Main Results
Despite the supplement’s excellent tolerability and high treatment adherence (96.8% in the cranberry group), the study results showed no significant improvements in the following areas:
- Changes in NF-kB and Nrf2 expression.
- Reductions in CRP, IL-6, and TBARS levels.
- Alterations in renal function.
Interpretation of Results
Individual Variability
Factors such as age, diet, gut microbiota status, and genetic polymorphisms can influence the bioavailability and efficacy of cranberry polyphenols.
Comparison with Previous Studies
In studies on healthy individuals or those with metabolic syndrome, cranberry juice reduced lipid oxidation markers and improved lipid profiles. However, differences in populations, dosages, and supplement forms (juice vs. extract) make direct comparisons challenging.
If you are interested in creating or manufacturing a cranberry-based product:
Source: May 2024, “Effects of Cranberry Extract (Vaccinium macrocarpon) Supplementation on Lipid Peroxidation and Inflammation in Patients with Chronic Kidney Disease (Stages 3-4): A Randomized Controlled Trial,” PubMed
